BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month ...
AT03-65 is the first program utilizing AxcynDOTâ„¢, a proprietary payload with a differentiated mechanism of action, to enter clinical development SINGAPORE, Jan. 15, 2025 /PRNewswire/ -- Axcynsis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback